Valuation: Indivior Pharmaceuticals, Inc.

Market Cap 4.46B 3.82B 3.57B 3.27B 6.15B 427B 6.27B 42.29B 16.49B 214B 16.76B 16.39B 708B P/E 2026 *
10.2x
P/E 2027 * 9.2x
Enterprise Value 4.45B 3.81B 3.56B 3.26B 6.13B 426B 6.25B 42.17B 16.44B 213B 16.71B 16.35B 706B EV / Sales 2026 *
3.34x
EV / Sales 2027 * 2.78x
Free-Float
97.98%
Yield 2026 *
-
Yield 2027 * -
1 day-3.23%
1 week-1.15%
Current month-5.57%
1 month-3.43%
3 months+0.51%
6 months+11.48%
Current year+5.30%
1 week 37.64
Extreme 37.64
40
1 month 35.76
Extreme 35.76
41.65
Current year 27.68
Extreme 27.68
42.81
1 year 22.22
Extreme 22.22
42.81
3 years 7.33
Extreme 7.33
42.81
5 years 7.33
Extreme 7.33
42.81
10 years 1.75
Extreme 1.75
42.81
Date Insider Type Main position Quantity % Market Cap.
8/5/26 A Buy

Controller/Auditor

1,500 0.0012%
7/10/26 A Sell

Chief Scientific Officer

-18,586 0.0152%
5/13/26 A Free

Director

6,518 0.0053%
Change 5-day change 1-year change 3-year change Capi.($)
-3.23%-1.15%+56.44%+70.56% 4.61B
-2.81%+2.93%+76.40%+127.73% 1,141B
-2.21%+2.02%+49.50%+55.01% 659B
-1.56%+4.39%+25.19%+74.39% 470B
+1.20%+2.62%+41.69%+45.78% 366B
-0.61%+2.10%+23.43%+41.34% 302B
+0.32%+3.25%+0.94%+13.42% 254B
-1.95%+3.80%+46.31%+65.66% 239B
-1.10%-0.70%-14.31%-52.66% 207B
-2.82%+3.84%+20.81%+89.04% 183B
Average -1.48%+2.47%+32.64%+53.03% 382.56B
Weighted average by Cap. -1.64%+3.11%+43.50%+70.86%

Financials

2026 *2027 *
Net sales 1.33B 1.14B 1.06B 976M 1.83B 127B 1.87B 12.62B 4.92B 63.87B 5B 4.89B 211B 1.4B 1.2B 1.12B 1.03B 1.93B 134B 1.97B 13.26B 5.17B 67.11B 5.25B 5.14B 222B
Net income 474M 406M 379M 348M 653M 45.38B 666M 4.49B 1.75B 22.74B 1.78B 1.74B 75.29B 530M 454M 423M 388M 730M 50.71B 744M 5.02B 1.96B 25.41B 1.99B 1.95B 84.14B
Net Debt -12.5M -10.7M -9.99M -9.16M -17.22M -1.2B -17.56M -118M -46.18M -599M -46.94M -45.91M -1.98B -570M -488M -455M -418M -785M -54.54B -801M -5.4B -2.11B -27.33B -2.14B -2.09B -90.49B
Logo Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
833
Date Price Change Volume
20/08/26 $37.78 -3.23% 1,442,317
19/08/26 $39.04 -0.99% 2,476,877
18/08/26 $39.43 +0.90% 2,338,564
17/08/26 $39.08 +0.18% 2,018,200
14/08/26 $39.01 +2.07% 988,395
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
37.78USD
Average target price
49.00USD
Spread / Average Target
+29.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INDV Stock